{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:30:38Z","timestamp":1790767838812,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007890","name":"University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ajt.2023.10.006","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T02:43:07Z","timestamp":1697856187000},"page":"468-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study"],"prefix":"10.1016","volume":"24","author":[{"given":"Wesam","family":"Aleyadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Verna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Elbeshbeshy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6352","authenticated-orcid":false,"given":"Mark S.","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleman","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jama","family":"Darling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-2475","authenticated-orcid":false,"given":"Richard K.","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-1179","authenticated-orcid":false,"given":"Andrew","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-5579","authenticated-orcid":false,"given":"Lucy","family":"Akushevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danie","family":"La","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4143-1950","authenticated-orcid":false,"given":"Norah","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2211","authenticated-orcid":false,"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajt.2023.10.006_bib1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2018.11.009","article-title":"Mortality and kidney transplantation outcomes among hepatitis C virus\u2013seropositive maintenance dialysis patients: a retrospective cohort study","volume":"73","author":"Sawinski","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.ajt.2023.10.006_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12829","article-title":"Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney","volume":"20","author":"Shelton","year":"2018","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.ajt.2023.10.006_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2012.03.015","article-title":"Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus\u2013positive kidney transplant recipients","volume":"60","author":"Kucirka","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.ajt.2023.10.006_bib4","first-page":"S71","article-title":"Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients","volume":"22","author":"Sise","year":"2018","journal-title":"Hemodial Int"},{"issue":"1","key":"10.1016\/j.ajt.2023.10.006_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M20-1468","article-title":"Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis c-negative recipients: an open-label nonrandomized study","volume":"174","author":"Durand","year":"2021","journal-title":"Ann Intern Med"},{"issue":"17","key":"10.1016\/j.ajt.2023.10.006_bib6","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ajt.2023.10.006_bib7","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1111\/ajt.15530","article-title":"Transplantation of kidneys from hepatitis C\u2013infected donors to hepatitis C\u2013negative recipients: single center experience","volume":"19","author":"Molnar","year":"2019","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2023.10.006_bib8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2020.10.017","article-title":"Transplantation of kidneys from hepatitis C virus-infected donors to hepatitis C virus-negative recipients: one-year kidney allograft outcomes","volume":"77","author":"Molnar","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.ajt.2023.10.006_bib9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/ajt.15583","article-title":"Fibrosing cholestatic hepatitis after kidney transplantation from hcv-viremic donors to hcv-negative recipients: a unique complication in the DAA era","volume":"20","author":"Kapila","year":"2020","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2023.10.006_bib10","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.16565","article-title":"Hepatitis C\u2013associated focal proliferative glomerulonephritis in an aviremic recipient of a hepatitis C\u2013positive antibody donor liver","volume":"21","author":"Bohorquez","year":"2021","journal-title":"Am J Transplant"},{"issue":"24","key":"10.1016\/j.ajt.2023.10.006_bib11","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of hcv-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ajt.2023.10.006_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus\u2013infected donors to noninfected recipients: an open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.ajt.2023.10.006_bib13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"27","key":"10.1016\/j.ajt.2023.10.006_bib14","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for hcv genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ajt.2023.10.006_bib15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (expedition-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ajt.2023.10.006_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-pick c1\u2013like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ajt.2023.10.006_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (redcap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"issue":"3","key":"10.1016\/j.ajt.2023.10.006_bib18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2017.07.025","article-title":"Public-private partnership: targeting real-world data for hepatitis C direct-acting antivirals","volume":"153","author":"Mishra","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ajt.2023.10.006_bib19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ajt.2023.10.006_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.ajt.2023.10.006_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of hcv infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.ajt.2023.10.006_bib22","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/lt.24614","article-title":"Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients","volume":"22","author":"Kwok","year":"2016","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.ajt.2023.10.006_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-2600(19)30268-1","article-title":"Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial","volume":"8","author":"Cypel","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ajt.2023.10.006_bib24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/TP.0000000000001708","article-title":"International liver transplantation society consensus statement on hepatitis C management in liver transplant candidates","volume":"101","author":"Terrault","year":"2017","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.ajt.2023.10.006_bib25","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1111\/ajt.15053","article-title":"Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy","volume":"18","author":"Chan","year":"2018","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2023.10.006_bib26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cgh.2016.07.035","article-title":"Acute rejection increases risk of graft failure and death in recent liver transplant recipients","volume":"15","author":"Levitsky","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.ajt.2023.10.006_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent hcv infection in recipients of organs from hcv-infected donors: a phase 3, single-centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ajt.2023.10.006_bib28","series-title":"Paper presented at: 2021 American Transplant Congress","article-title":"Pilot study for the use of shortened preemptive therapy with glecaprevir\/pibrentasvir (g\/p) and ezetimibe in hepatitis c seronegative solid organ transplant recipients (kidney and heart) of hepatitis c viremic donors","author":"Aqel","year":"2021"},{"issue":"2","key":"10.1016\/j.ajt.2023.10.006_bib29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ajt.15099","article-title":"Abt PL Trends among kidney transplant candidates in the United States: sifting through the tea leaves","volume":"19","author":"Gupta","year":"2019","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2023.10.006_bib30","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.15054","article-title":"Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy","volume":"18","author":"Gupta","year":"2018","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2023.10.006_bib31","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/lt.22354","article-title":"Hepatitis B immunoglobulin and\/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review","volume":"17","author":"Cholongitas","year":"2011","journal-title":"Liver Transpl"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613523007967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613523007967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:41:29Z","timestamp":1761630089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613523007967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1600613523007967"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2023.10.006","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2023.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}